Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.40 |
| ▸ | DHFR | P00374 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GNRHR | P30968 | 2/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982522 | 0.85 | DHFR (0.53) | GRM2DHFRLMNATP53 | |
| SCHEMBL4990769 | 0.84 | MTNR1B (0.45) | GRM2DHFR | |
| SCHEMBL4988449 | 0.81 | DHFR (0.45) | GRM2DHFR | |
| SCHEMBL4985337 | 0.80 | DHFR (0.52) | DHFR | |
| SCHEMBL4984991 | 0.79 | KMT2A (0.43) | GRM2TAAR1TP53 | |
| SCHEMBL4985030 | 0.79 | SIGMAR1 (0.50) | — | |
| SCHEMBL4986744 | 0.78 | HSP90AB1 (0.50) | DHFRTP53 | |
| SCHEMBL4985170 | 0.78 | KDM4E (0.56) | DHFRLMNA | |
| SCHEMBL13532718 | 0.76 | MKNK1 (0.33) | GRM2LMNATP53GNRHR | |
| SCHEMBL4983022 | 0.75 | KDM4E (0.46) | TAAR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | GRM2 332/4885DHFR 4248/4885KDR 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.